Neutrophil–lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer

: Current Oncology Neutrophil–lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer 2018.04.25.

Curr Oncol. 2018 Apr; 25(2): e113–e119. 논문 보기

Purpose

The neutrophil–lymphocyte ratio (nlr) has been reported to correlate with patient outcome in several cancers, including breast cancer. We evaluated whether the nlr can be a predictive factor for pathologic complete response (pcr) after neoadjuvant chemotherapy (nac) in patients with triple-negative breast cancer (tnbc).

Methods

We analyzed the correlation between response to nac and various factors, including the nlr, in 87 patients with tnbc who underwent nac. In addition, we analyzed the association between the nlr and recurrencefree survival (rfs) in patients with tnbc.

Results

Of the 87 patients, 25 (28.7%) achieved a pcr. A high Ki-67 index and a low nlr were significantly associated with pcr. The pcr rate was higher in patients having a high Ki-67 index (≥15%) than in those having a low Ki-67 index (35.7% vs. 0%, p = 0.002) and higher in patients having a low nlr (≤1.7) than in those having a high nlr (42.1% vs. 18.4%, p = 0.018). In multiple logistic analysis, a low nlr remained the only predictive factor for pcr (odds ratio: 4.274; p = 0.008). In the survival analysis, the rfs was significantly higher in the low nlr group than in the high nlr group (5-year rfs rate: 83.7% vs. 66.9%; log-rank p = 0.016).

▲ 이전글 Impact of Nodule Size on Malignancy Risk Differs according to the Ultrasonography Pattern of Thyroid Nodules 관**
▼ 다음글 Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer 관**

1 2 3

个人信息保护负责人	{{COMPANY_PRIVACY_OFFICER}}
联系方式	02-829-9000 / {{COMPANY_EMAIL}}

隐私政策